How effective is lorlatinib (lorlatinib) in treating lung cancer? Domestic and foreign research data and patient survival analysis

Lorlatinib (Lolatinib) is a third-generation ALK/ROS1 tyrosine kinase inhibitor, mainly used to treat ALK positive non-small cell lung cancer (NSCLC), especially in patients after failure of other ALK inhibitors (such as crizotinib, alectinib). Compared with previous generation drugs, lorlatinib (lorlatinib) has stronger brain penetration and is particularly effective for lung cancer patients with brain metastases, so it is widely used in clinical treatment.

Domestic and foreign research data

The clinical efficacy of lorlatinib has been verified in multiple international studies. According to data from a global multi-center clinical study (the CROWN study), lorlatinib (lorlatinib) has shown significant efficacy as first-line treatment in patients with ALK-positive non-small cell lung cancer. In this study, the objective response rate (ORR) was 76% with lorlatinib (lorlatinib) in participants who had not received any ALK inhibitors. , the progression-free survival (PFS) is 12.9 months, which is much higher than other first-line ALK inhibitors (such as crizotinib). This study also shows that in patients with brain metastases, lorlatinib (lorlatinib) has extremely high efficacy and can significantly improve the survival and quality of life of patients with brain metastases.

In second-line treatment, lorlatinib also showed good results. In a study called the BLOOM trial, researchers found that for patients who had developed resistance to previous generations of ALK inhibitors, The objective response rate of an>lorlatinib was 32%, and the response rate in patients with brain metastases was even higher, reaching 46%. In addition, lorlatinib also has significant advantages in terms of progression-free survival (PFS) and overall survival (OS). These data demonstrate that lorlatinib (lorlatinib) performs well in the treatment of ALK-positive non-small cell lung cancer, not only in treatment-naïve patients but also in drug-resistant patients.

Survival analysis

According to current research, lorlatinib has a significant prolonging effect on the survival of patients with ALKpositive non-small cell lung cancer. Especially in patients with brain metastases, lorlatinib (lorlatinib) significantly improved survival. Studies have shown that lorlatinib (lorlatinib) is far more effective in treating brain metastases than other ALK inhibitors and can effectively control the progression of brain metastases. In the CROWN study, the patient's progression-free survival reached 12.9 months, and in patients with brain metastases, the treatment effect was more significant. Additionally, in a trial ofREAL-1lorlatinib in pre-resistantALKpositive lung cancer patients have shown extremely high efficacy, and the survival period of some patients has even reached more than 2 years. This is of great significance for patients who previously could only rely on chemotherapy and radiotherapy.

Notably, the prolonged survival associated with lorlatinib is not only associated with its significant efficacy but also with its lower incidence of side effects. Although side effects of lorlatinib include high cholesterol, increased blood sugar, fatigue, diarrhea, etc., lorlatinib is better tolerated than other treatments, and most side effects can be alleviated after dose adjustment. This allows patients to maintain treatment for a longer period of time, further extending survival.

Patient feedback and quality of life

Feedback from patients also further verified the efficacy of lorlatinib (lorlatinib) and its improvement in quality of life. Many patients report significant improvement in symptoms after receiving treatment, especially in the relief of pulmonary symptoms such as dyspnea and cough. Especially for patients with brain metastases, many patients have significantly reduced symptoms such as headaches and blurred vision after using lorlatinib, and some patients have even seen their brain metastases shrink. These positive feedbacks indicate that lorlatinib (lorlatinib) can not only effectively prolong patients' survival, but also significantly improve their quality of life.

Overall, lorlatinib as a third-generationALK inhibitor, has demonstrated excellent efficacy and longer survival for patients with ALK-positive non-small cell lung cancer, especially those with brain metastases. Research data and clinical feedback at home and abroad have shown that lorlatinib (lorlatinib) performs well in both first-line and second-line treatment, especially in patients with brain metastases. Although there are some side effects to be aware of when using lorlatinib, such as high cholesterol and elevated blood sugar, its therapeutic efficacy and improved survival undoubtedly make it an important treatment option for ALK-positive non-small cell lung cancer.

Reference link:https://www.lorbrena.com/